Viral Content

Considering requests for compassionate use of experimental drugs remains one of the hardest, most complex tasks that any health-care company faces, as Helen Ouyang writes [“Hashtag Prescription,” Essay, June]. Patients make these requests when they are at their most vulnerable — when they have not responded to available treatments or are not eligible for clinical trials. In an effort to create a fair and transparent process for evaluating compassionate-use requests, Janssen/Johnson & Johnson launched an innovative collaboration with the Division of Medical Ethics at the NYU School of Medicine, which has been at the forefront of the conversation about…